Call 0334-1324952 for a free consultation and an honest quote
The intersection of metabolic dysfunction and psoriatic disease represents a promising frontier for therapeutic innovation
While non-modifiable risks like age, gender, and genetics are well-known, emerging evidence underscores that obesity, metabolic syndrome, and gut dysbiosis are potent, modifiable risk factors, intricately linked to daily dietary patterns (8, 9)
No changes were made to the endpoints for the comparison of tirzepatide versus dulaglutide in the expanded population because we observed high concordance with SURPASS-CVOT estimates in the primary composite endpoint as well as mortality in the benchmarking study
To see which medications are available, visit the Cost Plus Drugs medications page.
Taylor PM, Luangdilok CH, Sear JW